https://gabi-journal-net.server1.ech.be/articles 2026-05-22T10:53:00+00:00 https://gabi-journal-net.server1.ech.be/20121-table-of-contents.html 2014-10-22T11:45:57+00:00 https://gabi-journal-net.server1.ech.be/20134-gabi-journal-table-of-contents.html 2014-10-22T12:53:41+00:00 https://gabi-journal-net.server1.ech.be/2401.html 2014-11-03T08:29:10+00:00 https://gabi-journal-net.server1.ech.be/the-potential-for-doctors-to-contribute-to-biosimilar-guidelines.html 2015-04-21T07:45:45+00:00 https://gabi-journal-net.server1.ech.be/20153-gabi-journal-table-of-contents.html 2016-07-04T07:39:59+00:00 https://gabi-journal-net.server1.ech.be/alleviating-concerns-around-generic-antiepileptic-medications.html 2016-10-03T12:34:07+00:00 https://gabi-journal-net.server1.ech.be/the-case-for-biosimilars-a-payers-perspective.html 2016-10-03T12:35:29+00:00 https://gabi-journal-net.server1.ech.be/iapo-launched-the-patient-centred-healthcare-indicators-review.html 2016-10-03T12:39:17+00:00 https://gabi-journal-net.server1.ech.be/eortc-continues-to-support-the-appropriate-treatment-of-adult-patients-with-g-csf-to-prevent-febrile-neutropenia-guideline-updates.html 2016-10-03T12:40:26+00:00 https://gabi-journal-net.server1.ech.be/new-chmp-guideline-on-immunogenicity-of-monoclonal-antibodies.html 2016-10-03T12:40:52+00:00 https://gabi-journal-net.server1.ech.be/austria-increases-dialogue-in-order-to-involve-physicians-more-with-biosimilars.html 2016-10-03T12:42:39+00:00 https://gabi-journal-net.server1.ech.be/the-generic-pharmaceutical-industry-moving-beyond-incremental-innovation-towards-re-innovation.html 2016-10-03T12:44:37+00:00 https://gabi-journal-net.server1.ech.be/similar-biologics-approved-and-marketed-in-india.html 2016-10-03T12:47:58+00:00 https://gabi-journal-net.server1.ech.be/pmda-update-the-current-situation-and-future-directions.html 2016-10-03T12:49:06+00:00 https://gabi-journal-net.server1.ech.be/biosimilars-in-the-european-market.html 2016-10-03T12:50:39+00:00 https://gabi-journal-net.server1.ech.be/current-status-of-biopharmaceuticals-in-iran-s-pharmaceutical-market.html 2016-10-03T12:51:23+00:00 https://gabi-journal-net.server1.ech.be/20163-gabi-journal-table-of-contents.html 2016-10-31T11:59:36+00:00 https://gabi-journal-net.server1.ech.be/access-to-liposomal-generic-formulations-beyond-ambisome-and-doxilcaelyx.html 2016-11-14T09:09:48+00:00 https://gabi-journal-net.server1.ech.be/how-do-regional-sickness-funds-encourage-more-rational-use-of-medicines-including-the-increase-of-generic-uptake-a-case-study-from-austria.html 2016-11-14T09:12:29+00:00 https://gabi-journal-net.server1.ech.be/challenges-to-generic-medicines-utilization-in-yemeni-healthcare-system.html 2016-11-21T08:28:18+00:00 https://gabi-journal-net.server1.ech.be/biosimilarity-in-latin-america.html 2016-11-21T08:32:03+00:00 https://gabi-journal-net.server1.ech.be/why-bioequivalence-and-unconditional-interchangeability-of-generic-drugs-are-not-the-same.html 2016-11-21T08:32:57+00:00 https://gabi-journal-net.server1.ech.be/biosimilars-in-oncology-current-and-future-perspectives.html 2016-11-21T08:34:05+00:00 https://gabi-journal-net.server1.ech.be/update-on-clinical-practice-guideline-on-the-use-of-epoetin-and-darbepoetin-in-adult-patients-with-cancer.html 2016-11-21T08:35:32+00:00 https://gabi-journal-net.server1.ech.be/20162-gabi-journal-table-of-contents.html 2017-01-04T12:22:27+00:00 https://gabi-journal-net.server1.ech.be/20164-gabi-journal-table-of-contents.html 2017-03-09T16:26:30+00:00 https://gabi-journal-net.server1.ech.be/biosimilar-monoclonal-antibodies-time-for-a-regulatory-rethink.html 2017-03-29T10:34:50+00:00 https://gabi-journal-net.server1.ech.be/ongoing-initiatives-in-the-republic-of-srpska-to-enhance-prescribing-efficiency-influence-and-future-directions.html 2017-03-29T10:36:55+00:00 https://gabi-journal-net.server1.ech.be/commentary-on-the-recommendations-of-the-european-society-for-organ-transplantation-advisory-committee-on-generic-substitution-of-immunosuppressive-drugs.html 2017-03-29T10:37:28+00:00 https://gabi-journal-net.server1.ech.be/italys-final-position-paper-on-biosimilars-and-new-price-and-reimbursement-pathway.html 2017-03-29T10:39:05+00:00 https://gabi-journal-net.server1.ech.be/assessing-biosimilarity-using-the-method-of-generalized-pivotal-quantities.html 2017-03-29T10:40:20+00:00 https://gabi-journal-net.server1.ech.be/efficient-production-of-recombinant-parathyroid-hormone-rpth-fragment-1-34-in-the-methylotrophic-yeast-hansenula-polymorpha.html 2017-03-29T10:41:32+00:00 https://gabi-journal-net.server1.ech.be/maximizing-quality-in-the-manufacture-of-biologicals.html 2017-03-29T10:47:09+00:00 https://gabi-journal-net.server1.ech.be/suggested-evaluation-of-biological-drugs-role-for-who-editors-response.html 2017-03-29T10:49:34+00:00 https://gabi-journal-net.server1.ech.be/legislative-efforts-to-limit-prescription-information-sharing-between-patients-and-healthcare-providers-represent-a-serious-threat-to-the-health-and-safety-of-the-american-nation.html 2017-03-29T10:51:36+00:00 https://gabi-journal-net.server1.ech.be/biosimilars-naming-and-prescribing-policy-in-australia.html 2017-03-29T10:52:10+00:00 https://gabi-journal-net.server1.ech.be/who-leadership-in-public-safety-on-biosimilars-to-be-commended.html 2017-03-29T10:52:43+00:00 https://gabi-journal-net.server1.ech.be/biosimilar-development-and-regulation-in-japan.html 2017-03-29T10:58:50+00:00 https://gabi-journal-net.server1.ech.be/biosimilarity-of-anticancer-monoclonal-antibodies-in-the-clinic.html 2017-03-29T11:23:45+00:00 https://gabi-journal-net.server1.ech.be/the-biosimilar-name-debate-whats-at-stake-for-public-health.html 2017-03-29T11:24:38+00:00 https://gabi-journal-net.server1.ech.be/common-or-distinct-inn-for-biosimilars-only-characteristics-of-the-active-substance-prior-to-formulation-should-be-considered.html 2017-03-29T11:59:39+00:00 https://gabi-journal-net.server1.ech.be/alternative-statistical-strategies-for-biosimilar-drug-development.html 2017-03-29T12:02:45+00:00 https://gabi-journal-net.server1.ech.be/statistical-considerations-for-the-development-of-biosimilar-products.html 2017-03-29T12:11:08+00:00 https://gabi-journal-net.server1.ech.be/20172-gabi-journal-table-of-contents.html 2017-06-21T13:09:06+00:00 https://gabi-journal-net.server1.ech.be/20173-gabi-journal-table-of-contents.html 2017-10-30T15:25:30+00:00 https://gabi-journal-net.server1.ech.be/20181-gabi-journal-table-of-contents.html 2018-05-23T07:18:37+00:00 https://gabi-journal-net.server1.ech.be/2018-2-gabi-journal-table-of-contents.html 2018-09-05T14:14:23+00:00 https://gabi-journal-net.server1.ech.be/20161-gabi-journal-table-of-contents.html 2018-11-27T11:58:30+00:00 https://gabi-journal-net.server1.ech.be/20151-gabi-journal-table-of-contents.html 2018-11-27T12:11:24+00:00 https://gabi-journal-net.server1.ech.be/20144-gabi-journal-table-of-contents.html 2018-11-27T12:16:00+00:00 https://gabi-journal-net.server1.ech.be/2400.html 2018-11-27T13:28:59+00:00 https://gabi-journal-net.server1.ech.be/20122-gabi-journal-table-of-contents.html 2018-11-27T13:32:39+00:00 https://gabi-journal-net.server1.ech.be/20133-gabi-journal-table-of-contents.html 2018-11-27T13:36:22+00:00 https://gabi-journal-net.server1.ech.be/20143-gabi-journal-table-of-contents.html 2018-11-27T13:40:47+00:00 https://gabi-journal-net.server1.ech.be/20154-gabi-journal-table-of-contents.html 2018-11-27T13:43:28+00:00 https://gabi-journal-net.server1.ech.be/2018-3-gabi-journal-table-of-contents.html 2019-01-09T17:48:38+00:00 https://gabi-journal-net.server1.ech.be/regional-tenders-on-biosimilars-in-italy-potentially-competitive.html 2019-01-20T18:10:08+00:00 https://gabi-journal-net.server1.ech.be/what-pricing-and-reimbursement-policies-to-use-for-off-patent-biologicals-results-from-the-ebe-2014-biological-medicines-policy-survey.html 2019-01-29T09:05:19+00:00 https://gabi-journal-net.server1.ech.be/complexity-in-the-making-non-biological-complex-drugs-nbcds-and-the-pharmacopoeias.html 2019-01-29T10:02:34+00:00 https://gabi-journal-net.server1.ech.be/pricing-strategies-for-pharmaceuticals-in-developing-countries-what-options-do-we-have.html 2019-01-29T10:28:59+00:00 https://gabi-journal-net.server1.ech.be/ocular-emulsions-and-dry-eye-a-case-study-of-a-non-biological-complex-drug-product-delivered-to-a-complex-organ-to-treat-a-complex-disease.html 2019-01-29T10:29:44+00:00 https://gabi-journal-net.server1.ech.be/regional-regulatory-processes-for-the-approval-of-biosimilars-differences-and-similarities.html 2019-01-30T14:28:43+00:00 https://gabi-journal-net.server1.ech.be/retrospective-chart-review-disrupted-anaemia-control-in-haemodialysis-patients-following-the-switch-to-an-iron-sucrose-similar-iss-after-long-term-treatment-with-the-originator-iron-sucrose-is.html 2019-01-30T14:38:27+00:00 https://gabi-journal-net.server1.ech.be/gnrh-agonists-and-antagonists-in-prostate-cancer.html 2019-01-30T14:43:19+00:00 https://gabi-journal-net.server1.ech.be/subsequent-entry-biologics-biosimilars-in-canada-approaches-to-interchangeability-and-the-extrapolation-of-indications-and-uses.html 2019-01-30T14:46:07+00:00 https://gabi-journal-net.server1.ech.be/biosimilars-collaboration-at-amgen-and-actavis.html 2019-01-30T14:47:57+00:00 https://gabi-journal-net.server1.ech.be/ecco-2013-survey-highlights-lack-of-confidence-in-biosimilars.html 2019-01-30T14:49:08+00:00 https://gabi-journal-net.server1.ech.be/access-to-alternative-biopharmaceuticals-in-low-and-middle-income-countries.html 2019-01-30T14:56:45+00:00 https://gabi-journal-net.server1.ech.be/biosimilars-versus-biobetters-a-regulators-perspective.html 2019-01-30T14:57:51+00:00 https://gabi-journal-net.server1.ech.be/safety-assessment-of-biosimilars-in-europe-a-regulatory-perspective.html 2019-01-30T15:00:34+00:00 https://gabi-journal-net.server1.ech.be/tell-me-the-whole-story-the-role-of-product-labelling-in-building-user-confidence-in-biosimilars-in-europe.html 2019-01-30T15:03:46+00:00 https://gabi-journal-net.server1.ech.be/regulation-of-biologics-in-malaysia.html 2019-01-30T15:05:12+00:00 https://gabi-journal-net.server1.ech.be/2014-world-transplant-congress-san-francisco-california-usa-26-31-july-2014.html 2019-01-30T15:06:18+00:00 https://gabi-journal-net.server1.ech.be/biosimilars-patient-and-physician-acceptability-is-the-fifth-hurdle-to-market-competition.html 2019-01-30T15:18:21+00:00 https://gabi-journal-net.server1.ech.be/generic-medicines-policy-in-qatar.html 2019-01-30T15:19:11+00:00 https://gabi-journal-net.server1.ech.be/the-eu-regulatory-approach-to-generics-and-biosimilars-is-essentially-similar.html 2019-01-30T15:20:08+00:00 https://gabi-journal-net.server1.ech.be/payer-and-physician-evidence-and-discount-requirements-for-biosimilars-in-three-latin-american-countries.html 2019-01-30T15:21:15+00:00 https://gabi-journal-net.server1.ech.be/biosimilars-for-prescribers.html 2019-01-30T15:25:22+00:00 https://gabi-journal-net.server1.ech.be/generic-authorization-groundbreaking-regulatory-approach-to-closer-international-cooperation-on-the-rise-igdrp.html 2019-01-30T15:28:23+00:00 https://gabi-journal-net.server1.ech.be/generics-and-off-patent-biologicals-for-cancer-treatment-in-developing-countries.html 2019-01-30T15:30:11+00:00 https://gabi-journal-net.server1.ech.be/pro-generics-policies-and-the-backlog-in-medicines-registration-in-south-africa-implications-for-access-to-essential-and-affordable-medicines.html 2019-01-31T12:07:15+00:00 https://gabi-journal-net.server1.ech.be/norway-biosimilars-in-different-funding-systems-what-works.html 2019-01-31T12:13:00+00:00 https://gabi-journal-net.server1.ech.be/korean-regulations-for-biosimilars.html 2019-01-31T12:14:27+00:00 https://gabi-journal-net.server1.ech.be/update-on-us-state-legislation-on-biosimilars-substitution.html 2019-01-31T12:15:40+00:00 https://gabi-journal-net.server1.ech.be/online-biosimilars-resource-for-patients-across-latin-america.html 2019-01-31T12:16:51+00:00 https://gabi-journal-net.server1.ech.be/advances-in-analytical-characterization-of-biosimilars.html 2019-01-31T12:21:01+00:00 https://gabi-journal-net.server1.ech.be/access-to-safe-and-effective-biopharmaceuticals.html 2019-01-31T12:22:10+00:00 https://gabi-journal-net.server1.ech.be/the-challenges-of-nomenclature-inn-biosimilars-and-biological-qualifiers.html 2019-01-31T12:23:19+00:00 https://gabi-journal-net.server1.ech.be/biosimilars-patent-litigation-in-the-eu-and-the-us-a-comparative-strategic-overview.html 2019-01-31T12:24:33+00:00 https://gabi-journal-net.server1.ech.be/biosimilars-extrapolation-of-clinical-use-to-other-indications.html 2019-01-31T12:25:52+00:00 https://gabi-journal-net.server1.ech.be/generic-pregabalin-current-situation-and-implications-for-health-authorities-generics-and-biosimilars-manufacturers-in-the-future.html 2019-01-31T12:27:16+00:00 https://gabi-journal-net.server1.ech.be/substantial-savings-with-generics-in-austria-and-still-room-for-more.html 2019-01-31T12:30:26+00:00 https://gabi-journal-net.server1.ech.be/first-latin-american-educational-workshop-on-similar-biotherapeutic-products-mexico-city-mexico-20-january-2015.html 2019-01-31T12:31:43+00:00 https://gabi-journal-net.server1.ech.be/european-biosimilars-conference-highlights-extrapolation-as-key-issue.html 2019-01-31T12:35:17+00:00 https://gabi-journal-net.server1.ech.be/regulatory-requirements-for-the-development-and-registration-of-biosimilars-in-south-africa.html 2019-01-31T12:37:00+00:00 https://gabi-journal-net.server1.ech.be/bioequivalence-of-narrow-therapeutic-index-drugs-and-immunosuppressives.html 2019-01-31T12:39:56+00:00 https://gabi-journal-net.server1.ech.be/prescribing-practices-for-biosimilars-questionnaire-survey-findings-from-physicians-in-argentina-brazil-colombia-and-mexico.html 2019-01-31T12:41:01+00:00 https://gabi-journal-net.server1.ech.be/challenges-of-developing-generics-substitution-policies-in-low-and-middle-income-countries-lmics.html 2019-01-31T13:08:24+00:00 https://gabi-journal-net.server1.ech.be/measuring-performance-in-off-patent-drug-markets.html 2019-01-31T13:15:31+00:00 https://gabi-journal-net.server1.ech.be/immunogenicity-assessment-of-monoclonal-antibodies.html 2019-01-31T13:17:18+00:00 https://gabi-journal-net.server1.ech.be/readers-comments-2015-4.html 2019-01-31T13:18:30+00:00 https://gabi-journal-net.server1.ech.be/first-biosimilar-of-infliximab-approved-in-brazil-response-from-the-brazilian-ibd-society.html 2019-01-31T13:21:48+00:00 https://gabi-journal-net.server1.ech.be/waiver-of-consent-for-retrospective-chart-review-studies.html 2019-01-31T13:24:25+00:00 https://gabi-journal-net.server1.ech.be/life-begins-at-forty-hybridomas-ageing-technology-holds-promise-for-future-drug-discoveries.html 2019-01-31T13:26:48+00:00 https://gabi-journal-net.server1.ech.be/pricing-of-biosimilars-in-saudi-arabia.html 2019-01-31T13:28:05+00:00 https://gabi-journal-net.server1.ech.be/top-developments-in-biosimilars-during-2015.html 2019-01-31T13:32:32+00:00 https://gabi-journal-net.server1.ech.be/promoting-a-competitive-generics-market-in-the-us.html 2019-01-31T13:33:37+00:00 https://gabi-journal-net.server1.ech.be/the-case-for-reforming-drug-naming.html 2019-01-31T13:34:40+00:00 https://gabi-journal-net.server1.ech.be/assessment-of-the-interchangeability-between-generics.html 2019-01-31T13:38:21+00:00 https://gabi-journal-net.server1.ech.be/new-monoclonal-antibody-biosimilars-approved-in-2015-in-latin-america-position-statement-of-the-latin-american-forum-on-biosimilars-on-biosimilarity-interchangeability-and-extrapolation-of-indications.html 2019-01-31T13:41:24+00:00 https://gabi-journal-net.server1.ech.be/importance-of-manufacturing-consistency-of-the-glycosylated-monoclonal-antibody-adalimumab-humira-and-potential-impact-on-the-clinical-use-of-biosimilars.html 2019-01-31T13:42:26+00:00 https://gabi-journal-net.server1.ech.be/switching-from-the-infliximab-reference-product-to-ct-p13-in-patients-with-rheumatoid-arthritis-or-ankylosing-spondylitis-results-of-the-planetas-and-planetra-extension-studies.html 2019-01-31T13:48:03+00:00 https://gabi-journal-net.server1.ech.be/the-anti-tnf-biosimilar-ct-p13-had-comparable-efficacy-to-infliximab-in-rheumatoid-arthritis-over-one-year.html 2019-01-31T13:49:09+00:00 https://gabi-journal-net.server1.ech.be/is-the-eu-ready-for-non-biological-complex-drug-products.html 2019-01-31T13:51:23+00:00 https://gabi-journal-net.server1.ech.be/current-state-of-subsequent-entry-biologics-biosimilars-in-canada-a-view-from-regulatory-reimbursement-clinician-and-patient-perspectives.html 2019-01-31T13:53:43+00:00 https://gabi-journal-net.server1.ech.be/the-generic-medicines-system-in-italy-scenarios-for-sustainable-growth.html 2019-01-31T13:54:50+00:00 https://gabi-journal-net.server1.ech.be/pharmacovigilance-on-biologicals-and-biosimilars-a-danish-perspective.html 2019-01-31T13:55:53+00:00 https://gabi-journal-net.server1.ech.be/regional-management-of-biosimilars-in-germany.html 2019-01-31T13:56:56+00:00 https://gabi-journal-net.server1.ech.be/biosimilars-in-italy-a-gastroenterologists-view.html 2019-01-31T13:58:47+00:00 https://gabi-journal-net.server1.ech.be/first-turkish-interactive-workshop-on-regulation-and-approval-of-similar-biotherapeutic-productsbiosimilars-2-3-march-2016-ankara-turkey.html 2019-01-31T13:59:45+00:00 https://gabi-journal-net.server1.ech.be/demonstrating-interchangeability-and-biosimilarity-for-us-biosimilars.html 2019-01-31T14:00:47+00:00 https://gabi-journal-net.server1.ech.be/us-fda-proposals-for-naming-of-biologicals-and-labelling-of-biosimilars.html 2019-01-31T14:01:46+00:00 https://gabi-journal-net.server1.ech.be/competitive-effects-on-the-generics-industry.html 2019-01-31T14:03:00+00:00 https://gabi-journal-net.server1.ech.be/physicians-hippocrates-and-biosimilars-applying-ancient-principles-in-a-modern-society.html 2019-01-31T14:05:29+00:00 https://gabi-journal-net.server1.ech.be/naming-and-labelling-of-biologicals-the-perspective-of-hospital-and-retail-pharmacists.html 2019-01-31T14:06:30+00:00 https://gabi-journal-net.server1.ech.be/assessment-of-active-pharmaceutical-ingredients-in-drug-registration-procedures-in-pakistan-implications-for-the-future.html 2019-01-31T14:08:12+00:00 https://gabi-journal-net.server1.ech.be/cost-minimization-analysis-of-generic-equivalents-bortezomib-decitabine-and-capecitabine-in-comparison-to-the-originator-brand-medicines-in-colombia.html 2019-01-31T14:10:09+00:00 https://gabi-journal-net.server1.ech.be/regulatory-science-ireland-bridging-the-information-gap-on-biosimilar-medicines.html 2019-01-31T14:11:06+00:00 https://gabi-journal-net.server1.ech.be/where-does-the-value-of-value-added-pharmaceuticals-come-from.html 2019-01-31T14:13:21+00:00 https://gabi-journal-net.server1.ech.be/the-role-of-european-pharmacopoeia-monographs-in-setting-quality-standards-for-biotherapeutic-products.html 2019-01-31T14:14:28+00:00 https://gabi-journal-net.server1.ech.be/generic-medicines-entry-into-the-malaysian-pharmaceutical-market.html 2019-01-31T14:15:44+00:00 https://gabi-journal-net.server1.ech.be/data-requirements-to-demonstrate-biosimilarity-in-the-eu.html 2019-01-31T14:17:02+00:00 https://gabi-journal-net.server1.ech.be/effect-of-naming-on-pharmacists-perceptions-and-dispensing-of-biosimilars.html 2019-01-31T14:18:02+00:00 https://gabi-journal-net.server1.ech.be/essential-information-for-internists-on-biologicals-and-biosimilars.html 2019-01-31T14:18:47+00:00 https://gabi-journal-net.server1.ech.be/an-empirical-study-of-market-based-purchasing-policies-for-generic-pharmaceuticals-in-sweden.html 2019-01-31T14:19:52+00:00 https://gabi-journal-net.server1.ech.be/strategies-used-to-delay-or-prevent-access-to-affordable-generic-drugs-in-the-us.html 2019-01-31T14:21:00+00:00 https://gabi-journal-net.server1.ech.be/assuring-patient-centred-care-engaging-patients-with-rheumatoid-arthritis-in-disease-monitoring-and-pharmacovigilance.html 2019-02-10T13:58:48+00:00 https://gabi-journal-net.server1.ech.be/are-the-perspectives-regarding-the-use-of-biosimilars-in-the-setting-of-haematology-and-blood-and-marrow-transplant-changing.html 2019-02-11T15:14:21+00:00 https://gabi-journal-net.server1.ech.be/investigating-the-validity-of-biosimilar-extrapolation-and-interchangeability.html 2019-02-11T15:16:02+00:00 https://gabi-journal-net.server1.ech.be/improving-biosimilars-uptake-experience-gained-in-madrid-spain.html 2019-02-11T15:18:07+00:00 https://gabi-journal-net.server1.ech.be/reducing-healthcare-costs-and-building-trust-in-biosimilar-medicines.html 2019-02-11T15:20:31+00:00 https://gabi-journal-net.server1.ech.be/roundtable-on-biosimilars-with-european-regulators-and-medical-societies-brussels-belgium-12-january-2016.html 2019-02-11T15:21:54+00:00 https://gabi-journal-net.server1.ech.be/biosimilars-patent-litigation-in-canada-and-japan-a-comparative-strategic-overview-and-eu-and-us-update.html 2019-02-11T15:23:14+00:00 https://gabi-journal-net.server1.ech.be/supporting-biosimilarity-and-extrapolation.html 2019-02-11T15:25:23+00:00 https://gabi-journal-net.server1.ech.be/patent-expiry-dates-for-best-selling-biologicals.html 2019-02-11T15:26:52+00:00 https://gabi-journal-net.server1.ech.be/top-developments-in-biosimilars-during-2014.html 2019-02-12T12:22:46+00:00 https://gabi-journal-net.server1.ech.be/health-canadas-perspective-on-the-clinical-development-of-biosimilars-and-related-scientific-and-regulatory-challenges.html 2019-02-12T12:25:03+00:00 https://gabi-journal-net.server1.ech.be/amgens-move-into-the-biosimilars-market.html 2019-02-14T08:34:34+00:00 https://gabi-journal-net.server1.ech.be/international-alliance-of-patients-organizations-toolkit-for-biological-and-biosimilar-medicines.html 2019-02-14T08:38:36+00:00 https://gabi-journal-net.server1.ech.be/interchangeability-an-insurmountable-fifth-hurdle.html 2019-02-14T09:20:50+00:00 https://gabi-journal-net.server1.ech.be/top-developments-in-biosimilars-during-2013.html 2019-02-14T09:56:17+00:00 https://gabi-journal-net.server1.ech.be/analysis-of-european-policy-towards-generic-medicines.html 2019-02-14T10:00:46+00:00 https://gabi-journal-net.server1.ech.be/new-product-specific-bioequivalence-guidance.html 2019-02-14T10:03:59+00:00 https://gabi-journal-net.server1.ech.be/drug-shortages-hit-us-oncologists-hard.html 2019-02-17T17:08:07+00:00 https://gabi-journal-net.server1.ech.be/comparison-of-biosimilars-guidelines.html 2019-02-17T17:10:08+00:00 https://gabi-journal-net.server1.ech.be/weighing-up-the-cost-of-switching-to-biosimilars.html 2019-02-18T09:02:25+00:00 https://gabi-journal-net.server1.ech.be/is-australia-positioned-to-take-advantage-of-biosimilars.html 2019-02-18T09:16:07+00:00 https://gabi-journal-net.server1.ech.be/reducing-the-european-healthcare-budget-with-generics-and-biosimilars.html 2019-02-18T09:21:11+00:00 https://gabi-journal-net.server1.ech.be/critical-immunogenicity-differences-will-be-obscured-by-a-common-inn-for-biosimilars.html 2019-02-18T09:28:54+00:00 https://gabi-journal-net.server1.ech.be/immunogenicity-of-biosimilar-monoclonal-antibodies.html 2019-02-18T09:30:38+00:00 https://gabi-journal-net.server1.ech.be/us-state-legislation-on-biosimilars-substitution.html 2019-02-18T09:34:40+00:00 https://gabi-journal-net.server1.ech.be/licensing-and-prescribing-biosimilars-in-australia.html 2019-02-18T09:36:09+00:00 https://gabi-journal-net.server1.ech.be/steps-to-ensure-adequate-supply-of-biological-medicines-considerations-for-the-healthcare-provider.html 2019-02-18T09:43:15+00:00 https://gabi-journal-net.server1.ech.be/biosimilar-monoclonal-antibodies-challenges-and-opportunities-in-europe.html 2019-02-18T09:45:40+00:00 https://gabi-journal-net.server1.ech.be/the-future-of-biological-therapy-a-pathway-forward-for-biosimilars.html 2019-02-18T09:56:09+00:00 https://gabi-journal-net.server1.ech.be/health-authority-perspective-on-biosimilars.html 2019-02-18T09:57:42+00:00 https://gabi-journal-net.server1.ech.be/pharmacovigilance-of-biosimilars-challenges-and-possible-solutions.html 2019-02-18T10:03:39+00:00 https://gabi-journal-net.server1.ech.be/generics-policies-a-globally-relevant-implementation-challenge.html 2019-02-18T10:06:44+00:00 https://gabi-journal-net.server1.ech.be/20123-4-gabi-journal-table-of-contents.html 2019-02-18T10:08:54+00:00 https://gabi-journal-net.server1.ech.be/the-ethics-of-biosimilars.html 2019-02-18T10:18:04+00:00 https://gabi-journal-net.server1.ech.be/availability-and-procurement-of-generics-in-hospitals-among-medium-sized-european-countries.html 2019-02-18T10:56:57+00:00 https://gabi-journal-net.server1.ech.be/pathway-to-affordable-quality-assured-sources-of-pegylated-interferon-alpha-for-treating-hepatitis-c.html 2019-02-18T10:58:41+00:00 https://gabi-journal-net.server1.ech.be/new-eu-guidance-for-the-evaluation-of-medicinal-products-with-modified-drug-release-will-be-finished-by-the-middle-of-2014.html 2019-02-18T11:02:26+00:00 https://gabi-journal-net.server1.ech.be/views-of-physicians-and-patients-with-chronic-conditions-on-generic-medicines-in-greece-after-the-introduction-of-measures-to-promote-their-consumption-findings-from-a-qualitative-study.html 2019-02-18T11:06:41+00:00 https://gabi-journal-net.server1.ech.be/20142-gabi-journal-table-of-contents.html 2019-02-18T11:07:12+00:00 https://gabi-journal-net.server1.ech.be/perceptions-of-physicians-from-private-medical-centers-in-malaysia-about-generic-medicine-usage-a-qualitative-study.html 2019-02-18T11:20:10+00:00 https://gabi-journal-net.server1.ech.be/thank-you-to-reviewers-2012.html 2019-02-26T13:34:31+00:00 https://gabi-journal-net.server1.ech.be/thank-you-to-reviewers-2013.html 2019-02-26T13:35:00+00:00 https://gabi-journal-net.server1.ech.be/thank-you-to-reviewers-2014.html 2019-02-26T13:35:27+00:00 https://gabi-journal-net.server1.ech.be/thank-you-to-reviewers-2015.html 2019-02-26T13:35:58+00:00 https://gabi-journal-net.server1.ech.be/thank-you-to-reviewers-2016.html 2019-02-26T13:36:26+00:00 https://gabi-journal-net.server1.ech.be/thank-you-to-reviewers-2017.html 2019-02-26T13:36:55+00:00 https://gabi-journal-net.server1.ech.be/2018-4-gabi-journal-table-of-contents.html 2019-03-12T13:17:08+00:00 https://gabi-journal-net.server1.ech.be/the-eu-is-ready-for-non-biological-complex-medicinal-products.html 2019-09-05T08:17:30+00:00 https://gabi-journal-net.server1.ech.be/thank-you-to-reviewers-2018.html 2019-10-03T06:55:54+00:00 https://gabi-journal-net.server1.ech.be/national-and-regional-activities-by-sickness-funds-in-austria-to-encourage-the-rational-use-of-medicines.html 2019-10-28T10:13:04+00:00 https://gabi-journal-net.server1.ech.be/pharmaceutical-policy-interventions-in-times-of-economic-recession.html 2020-01-12T21:44:13+00:00 https://gabi-journal-net.server1.ech.be/what-pricing-and-reimbursement-policies-to-use-for-off-patent-biologicals-in-europe-results-from-the-second-ebe-biological-medicines-policy-survey.html 2020-01-16T09:51:44+00:00 https://gabi-journal-net.server1.ech.be/generic-prices-estimated-for-four-novel-cancer-drugs.html 2020-01-16T09:53:09+00:00 https://gabi-journal-net.server1.ech.be/top-developments-in-biosimilars-during-2017.html 2020-01-16T10:12:07+00:00 https://gabi-journal-net.server1.ech.be/analysis-of-drug-master-files-registered-in-japan-aiming-for-a-stable-supply-of-active-pharmaceutical-ingredients.html 2020-01-16T10:12:33+00:00 https://gabi-journal-net.server1.ech.be/the-impact-of-religion-on-human-embryonic-stem-cell-regulations-comparison-between-the-uk-germany-and-the-us.html 2020-01-16T10:12:52+00:00 https://gabi-journal-net.server1.ech.be/regulations-for-biotherapeutics-approval-in-colombia.html 2020-01-16T10:13:40+00:00 https://gabi-journal-net.server1.ech.be/barriers-to-generics-policy-reform-a-us-case-study.html 2020-01-16T10:14:03+00:00 https://gabi-journal-net.server1.ech.be/patent-expiry-dates-for-biologicals-2017-update.html 2020-01-16T10:14:24+00:00 https://gabi-journal-net.server1.ech.be/potential-changes-to-the-fda-approach-to-biosimilars-have-a-global-impact.html 2020-01-16T10:17:13+00:00 https://gabi-journal-net.server1.ech.be/patient-reported-outcome-measures-in-phase-iii-trials-of-ly2963016-insulin-glargine-and-reference-insulin-glargine-products-element-1-and-element-2.html 2020-01-16T10:17:40+00:00 https://gabi-journal-net.server1.ech.be/protein-heterogeneity-and-the-immunogenicity-of-biotherapeutics.html 2020-01-16T10:18:00+00:00 https://gabi-journal-net.server1.ech.be/rationalizing-fda-guidance-on-biosimilars-expediting-approvals-and-acceptance.html 2020-01-16T10:18:22+00:00 https://gabi-journal-net.server1.ech.be/how-to-realize-the-potential-of-off-patent-biologicals-and-biosimilars-in-europe-guidance-to-policymakers.html 2020-01-16T10:19:00+00:00 https://gabi-journal-net.server1.ech.be/biosimilar-regulation-and-approval-in-jordan.html 2020-01-16T10:19:46+00:00 https://gabi-journal-net.server1.ech.be/a-call-for-coherence-in-eu-legislation-to-promote-generics.html 2020-01-16T10:20:25+00:00 https://gabi-journal-net.server1.ech.be/eu-risk-sharing-agreements-between-2000-2015.html 2020-01-16T10:24:49+00:00 https://gabi-journal-net.server1.ech.be/how-does-generic-drug-policy-affect-market-prices.html 2020-01-16T10:25:12+00:00 https://gabi-journal-net.server1.ech.be/first-asean-educational-workshop-on-regulation-and-approval-of-biosimilars-similar-biotherapeutic-products-2017-report.html 2020-01-16T10:25:54+00:00 https://gabi-journal-net.server1.ech.be/nomenclature-for-biosimilars-a-continuing-thorny-issue.html 2020-01-16T10:29:14+00:00 https://gabi-journal-net.server1.ech.be/the-need-for-distinct-nomenclature-for-originator-and-biosimilar-products.html 2020-01-16T10:29:56+00:00 https://gabi-journal-net.server1.ech.be/us-generic-prescription-drug-markets-2004%e2%80%922016.html 2020-01-16T10:30:18+00:00 https://gabi-journal-net.server1.ech.be/2019-2-gabi-journal-table-of-contents.html 2020-01-30T10:22:48+00:00 https://gabi-journal-net.server1.ech.be/2019-3-gabi-journal-table-of-contents.html 2020-01-30T10:23:28+00:00 https://gabi-journal-net.server1.ech.be/are-there-biosimilar-orphan-drugs-for-gaucher-disease-an-overview-in-mexico.html 2020-02-04T14:41:00+00:00 https://gabi-journal-net.server1.ech.be/eu-member-states-have-tools-to-reduce-costs-of-bestseller-biologicals-but-can-they-use-them.html 2020-03-06T10:30:38+00:00 https://gabi-journal-net.server1.ech.be/the-impact-of-pharmaceutical-pricing-and-reimbursement-policies-on-generics-uptake-implementation-of-policy-options-on-generics-in-29-european-countries%e2%94%80an-overview.html 2020-03-11T15:23:02+00:00 https://gabi-journal-net.server1.ech.be/how-matrix-models-can-support-generic-medicine-prescribing.html 2020-03-11T15:26:28+00:00 https://gabi-journal-net.server1.ech.be/payers-endorse-generics-to-enhance-prescribing-efficiency-impact-and-future-implications-a-case-history-approach.html 2020-03-12T08:14:44+00:00 https://gabi-journal-net.server1.ech.be/what-lessons-can-be-learnt-from-the-launch-of-generic-clopidogrel.html 2020-03-12T08:17:46+00:00 https://gabi-journal-net.server1.ech.be/tighter-eu-rules-on-pharmacovigilance-for-biologicals.html 2020-03-12T08:22:21+00:00 https://gabi-journal-net.server1.ech.be/statin-generics-no-differences-in-efficacy-after-switching.html 2020-03-12T08:30:41+00:00 https://gabi-journal-net.server1.ech.be/reference-price-systems-stakeholder-dialogue-and-involvement.html 2020-03-12T08:52:24+00:00 https://gabi-journal-net.server1.ech.be/ich-q11-development-and-manufacture-of-drug-substances-chemical-and-biotechnological-biological-entities.html 2020-03-12T08:56:20+00:00 https://gabi-journal-net.server1.ech.be/a-clinicians-view-of-the-ethics-of-the-use-of-biosimilars.html 2020-03-12T08:57:52+00:00 https://gabi-journal-net.server1.ech.be/a-bioethicists-view-of-the-use-of-biosimilars.html 2020-03-12T09:05:55+00:00 https://gabi-journal-net.server1.ech.be/saving-money-in-the-european-healthcare-systems-with-biosimilars.html 2020-03-12T09:18:27+00:00 https://gabi-journal-net.server1.ech.be/health-professionals-in-the-risk-communication-process-on-counterfeit-medicines.html 2020-03-12T09:31:30+00:00 https://gabi-journal-net.server1.ech.be/terminology-for-biosimilars-a-confusing-minefield.html 2020-03-12T09:33:05+00:00 https://gabi-journal-net.server1.ech.be/reference-pricing-systems-in-europe-characteristics-and-consequences.html 2020-03-12T09:34:28+00:00 https://gabi-journal-net.server1.ech.be/the-medicrime-convention-criminalising-the-falsification-of-medicines-and-similar-crimes.html 2020-03-12T09:36:25+00:00 https://gabi-journal-net.server1.ech.be/biosimilars-considerations-in-light-of-the-italian-legal-framework.html 2020-03-19T10:27:36+00:00 https://gabi-journal-net.server1.ech.be/thank-you-to-reviewers-2019.html 2020-03-24T10:55:01+00:00 https://gabi-journal-net.server1.ech.be/recommendations-for-the-regulation-of-biosimilars-and-their-implementation-in-latin-america.html 2020-05-21T15:31:35+00:00 https://gabi-journal-net.server1.ech.be/innovator-companies-should-focus-on-innovations.html 2020-06-22T12:45:19+00:00 https://gabi-journal-net.server1.ech.be/generic-medicine-pricing-on-track-in-europe.html 2020-06-22T12:51:50+00:00 https://gabi-journal-net.server1.ech.be/generic-and-therapeutic-orphans.html 2020-06-22T12:54:17+00:00 https://gabi-journal-net.server1.ech.be/myths-questions-facts-about-generic-drugs-in-the-eu.html 2020-06-22T12:58:32+00:00 https://gabi-journal-net.server1.ech.be/a-review-of-patient-perspectives-on-generics-substitution-what-are-the-challenges-for-optimal-drug-use.html 2020-06-22T13:01:56+00:00 https://gabi-journal-net.server1.ech.be/european-payer-initiatives-to-reduce-prescribing-costs-through-use-of-generics.html 2020-06-22T13:03:31+00:00 https://gabi-journal-net.server1.ech.be/a-patient-centred-paradigm-for-the-biosimilars-market.html 2020-06-22T13:08:59+00:00 https://gabi-journal-net.server1.ech.be/biologicals-and-biosimilars-a-review-of-the-science-and-its-implications.html 2020-06-22T13:10:53+00:00 https://gabi-journal-net.server1.ech.be/a-review-of-generic-medicine-pricing-in-europe.html 2020-06-22T13:12:01+00:00 https://gabi-journal-net.server1.ech.be/rhythm.html 2020-06-22T13:14:25+00:00 https://gabi-journal-net.server1.ech.be/oncologists-urged-to-embrace-biosimilars-to-help-control-spiralling-costs-of-cancer-care.html 2020-06-22T13:27:48+00:00 https://gabi-journal-net.server1.ech.be/equal-protection-under-the-law-children-and-the-best-pharmaceuticals-for-children-act.html 2020-06-22T13:30:40+00:00 https://gabi-journal-net.server1.ech.be/generic-clopidogrel-the-medicines-agencys-perspective.html 2020-06-22T13:33:50+00:00 https://gabi-journal-net.server1.ech.be/regulatory-requirements-for-the-acceptance-of-foreign-comparator-products-in-the-participants-of-the-international-generic-drug-regulators-programme.html 2020-07-23T15:48:12+00:00 https://gabi-journal-net.server1.ech.be/an-evolving-role-for-non-governmental-organizations-dealing-with-registration-backlogs-and-rising-costs-the-example-of-cancer-biosimilars-in-south-africa.html 2020-09-02T08:36:27+00:00 https://gabi-journal-net.server1.ech.be/ongoing-activities-to-influence-the-prescribing-of-proton-pump-inhibitors-within-the-scottish-national-health-service-their-effect-and-implications.html 2020-10-07T10:18:29+00:00 https://gabi-journal-net.server1.ech.be/in-vitro-analytical-and-antibiotic-comparison-of-generic-moxifloxacin-against-e-coli-and-s-aureus-bacteria-strains.html 2020-10-07T10:29:23+00:00 https://gabi-journal-net.server1.ech.be/escalating-prices-of-generic-drugs-targeted-by-us-anti-gouging-legislation.html 2020-10-08T07:25:49+00:00 https://gabi-journal-net.server1.ech.be/biosimilar-infliximab-introduction-into-the-gastroenterology-care-pathway-in-a-large-acute-irish-teaching-hospital-a-story-behind-the-evidence.html 2020-10-09T06:34:57+00:00 https://gabi-journal-net.server1.ech.be/2020-3-gabi-journal-table-of-contents.html 2020-10-28T09:39:54+00:00 https://gabi-journal-net.server1.ech.be/2019-1-gabi-journal-table-of-contents.html 2020-10-30T07:42:36+00:00 https://gabi-journal-net.server1.ech.be/it-is-time-to-change-us-trade-policy-to-foster-access-to-medicines.html 2020-11-09T11:20:55+00:00 https://gabi-journal-net.server1.ech.be/poor-traceability-of-biologicals-in-uk-adr-reporting-indicates-the-need-for-improvements-to-ensure-patient-safety.html 2020-11-16T23:47:17+00:00 https://gabi-journal-net.server1.ech.be/pharmacy-chain-drives-choice-among-manufacturers-of-generic-drugs-in-the-us-medicare-population.html 2020-11-17T08:43:25+00:00 https://gabi-journal-net.server1.ech.be/an-ever-evolving-landscape-an-update-on-the-rapidly-changing-regulation-and-reimbursement-of-biosimilars-in-canada.html 2020-11-17T09:00:10+00:00 https://gabi-journal-net.server1.ech.be/1st-asean-overview-workshop-on-gmp-for-biologicals-biosimilars-2018-report.html 2020-11-17T10:16:09+00:00 https://gabi-journal-net.server1.ech.be/biosimilars-markets-us-and-eu-compared.html 2020-11-23T10:04:10+00:00 https://gabi-journal-net.server1.ech.be/clinical-trials-for-trastuzumab-biosimilars.html 2020-11-23T10:14:54+00:00 https://gabi-journal-net.server1.ech.be/policy-recommendations-for-a-sustainable-biosimilars-market-lessons-from-europe.html 2020-11-23T10:31:34+00:00 https://gabi-journal-net.server1.ech.be/global-challenges-in-the-manufacture-regulation-and-international-harmonization-of-gmp-and-quality-standards-for-biopharmaceuticals.html 2020-11-23T10:45:34+00:00 https://gabi-journal-net.server1.ech.be/importance-of-the-determination-of-the-higher-order-structure-in-the-in-use-stability-studies-of-biopharmaceuticals.html 2020-11-23T12:46:43+00:00 https://gabi-journal-net.server1.ech.be/2020-4-gabi-journal-table-of-contents.html 2020-12-02T09:39:03+00:00 https://gabi-journal-net.server1.ech.be/quality-standards-for-biopharmaceuticals-the-importance-of-good-manufacturing-practice.html 2021-01-06T11:09:00+00:00 https://gabi-journal-net.server1.ech.be/is-the-local-tolerance-of-injectable-biosimilars-too-underestimated.html 2021-01-27T15:16:37+00:00 https://gabi-journal-net.server1.ech.be/2020-1-gabi-journal-table-of-contents.html 2021-02-08T23:09:24+00:00 https://gabi-journal-net.server1.ech.be/2020-2-gabi-journal-table-of-contents.html 2021-02-08T23:10:33+00:00 https://gabi-journal-net.server1.ech.be/pricing-of-oral-generic-cancer-medicines-in-25-european-countries-findings-and-implications.html 2021-02-16T10:41:07+00:00 https://gabi-journal-net.server1.ech.be/safety-and-toxicity-of-biosimilars-eu-versus-us-regulation.html 2021-03-04T11:09:55+00:00 https://gabi-journal-net.server1.ech.be/2021-1-gabi-journal-table-of-contents.html 2021-03-09T09:26:49+00:00 https://gabi-journal-net.server1.ech.be/pharmaceutical-pricing-policy-in-saudi-arabia-findings-and-implications.html 2021-03-10T14:09:14+00:00 https://gabi-journal-net.server1.ech.be/qualitative-survey-based-evaluation-of-operability-and-convenience-for-the-etanercept-biosimilar-ylb113-in-a-unique-injection-pen-in-patients-with-rheumatoid-arthritis.html 2021-03-23T15:32:03+00:00 https://gabi-journal-net.server1.ech.be/pelmeg-a-biosimilar-pegfilgrastim-developed-in-the-context-of-evolving-regulatory-guidelines.html 2021-04-27T08:58:22+00:00 https://gabi-journal-net.server1.ech.be/2021-2-gabi-journal-table-of-contents.html 2021-06-22T08:52:04+00:00 https://gabi-journal-net.server1.ech.be/current-trends-for-biosimilars-in-the-latin-american-market.html 2021-06-22T10:47:59+00:00 https://gabi-journal-net.server1.ech.be/repurposing-non-oncology-drugs-for-cancer-treatment.html 2021-07-01T14:01:41+00:00 https://gabi-journal-net.server1.ech.be/austria-could-save-euros-256-million-by-using-more-generics.html 2021-08-26T12:56:05+00:00 https://gabi-journal-net.server1.ech.be/local-policies-on-biosimilars-are-they-designed-to-optimize-use-of-liberated-resources.html 2021-11-04T09:56:26+00:00 https://gabi-journal-net.server1.ech.be/a-white-paper-us-biosimilars-market-on-pace-with-europe.html 2021-11-04T10:01:05+00:00 https://gabi-journal-net.server1.ech.be/physicochemical-stability-of-the-bevacizumab-biosimilar-abp-215-after-preparation-and-storage-in-intravenous-bags.html 2021-11-04T10:03:02+00:00 https://gabi-journal-net.server1.ech.be/biosimilars-in-saudi-arabia-a-single-centre-open-label-case-series-examining-infliximab-switching.html 2022-01-19T08:44:07+00:00 https://gabi-journal-net.server1.ech.be/the-eu-regulatory-network-and-emerging-trends-a-review-of-quality-safety-and-clinical-development-programmes.html 2022-01-19T13:26:06+00:00 https://gabi-journal-net.server1.ech.be/2021-3-gabi-journal-table-of-contents.html 2022-02-01T08:30:23+00:00 https://gabi-journal-net.server1.ech.be/an-assessment-of-trends-in-the-iranian-pharmaceutical-market-following-domestic-production-of-selected-medications-2007%e2%80%922017-and-new-considerations-for-health-policymakers.html 2022-02-08T14:06:53+00:00 https://gabi-journal-net.server1.ech.be/continuous-manufacturing-versus-batch-manufacturing-benefits-opportunities-and-challenges-for-manufacturers-and-regulators.html 2022-02-08T14:21:33+00:00 https://gabi-journal-net.server1.ech.be/thank-you-to-reviewers-2020.html 2022-02-10T13:37:22+00:00 https://gabi-journal-net.server1.ech.be/pharmacovigilance-of-biosimilars-and-other-biologicals-within-the-hospital-current-practices-and-future-challenges.html 2022-04-04T10:43:58+00:00 https://gabi-journal-net.server1.ech.be/patent-expiry-dates-for-biologicals-2016-update.html 2022-04-04T10:44:44+00:00 https://gabi-journal-net.server1.ech.be/roundtable-on-biosimilars-pharmacovigilance-traceability-immunogenicity-15-november-2016-madrid-spain.html 2022-04-04T10:45:28+00:00 https://gabi-journal-net.server1.ech.be/biosimilar-product-labels-in-europe-what-information-should-they-contain.html 2022-04-04T10:46:09+00:00 https://gabi-journal-net.server1.ech.be/top-developments-in-biosimilars-during-2016.html 2022-04-04T10:47:43+00:00 https://gabi-journal-net.server1.ech.be/trends-and-challenges-in-biosimilars-pricing-and-reimbursement-policies-in-europe-and-beyond.html 2022-04-04T10:49:46+00:00 https://gabi-journal-net.server1.ech.be/strategies-for-pricing-of-pharmaceuticals-and-generics-in-developing-countries.html 2022-04-04T10:50:52+00:00 https://gabi-journal-net.server1.ech.be/overview-of-the-patent-expiry-of-non-tyrosine-kinase-inhibitors-approved-for-clinical-use-in-the-eu-and-usa.html 2022-04-04T10:53:03+00:00 https://gabi-journal-net.server1.ech.be/interchangeability-of-biosimilars-in-the-us-and-around-the-world.html 2022-04-04T10:53:57+00:00 https://gabi-journal-net.server1.ech.be/effective-generics-substitution.html 2022-04-04T10:55:00+00:00 https://gabi-journal-net.server1.ech.be/a-survey-of-australian-prescribers-views-on-the-naming-and-substitution-of-biologicals.html 2022-04-04T10:57:30+00:00 https://gabi-journal-net.server1.ech.be/pharmacovigilance-traceability-and-building-trust-in-biosimilar-medicines.html 2022-04-04T11:01:42+00:00 https://gabi-journal-net.server1.ech.be/to-prescribe-generics-is-to-play-with-the-life-of-the-patient-misconceptions-of-generics-in-guatemala.html 2022-04-04T11:06:48+00:00 https://gabi-journal-net.server1.ech.be/healthcare-professionals-will-accept-generic-hiv-treatments.html 2022-04-04T11:09:57+00:00 https://gabi-journal-net.server1.ech.be/next-generation-processing-of-monoclonal-antibodies.html 2022-04-04T13:04:38+00:00 https://gabi-journal-net.server1.ech.be/sourcing-innovator-products-in-the-age-of-biosimilar-research.html 2022-04-04T13:09:37+00:00 https://gabi-journal-net.server1.ech.be/biosimilar-monoclonal-antibodies-development-simplified.html 2022-04-04T13:14:41+00:00 https://gabi-journal-net.server1.ech.be/20152-gabi-journal-table-of-contents.html 2022-04-04T13:18:19+00:00 https://gabi-journal-net.server1.ech.be/austrian-medicines-authority-positive-towards-biosimilar-interchangeability.html 2022-04-04T13:24:15+00:00 https://gabi-journal-net.server1.ech.be/global-policies-on-pharmacy-mediated-substitution-of-biosimilars-a-summary.html 2022-04-04T13:29:41+00:00 https://gabi-journal-net.server1.ech.be/pharmacy-mediated-substitution-of-biosimilars-a-global-survey-benchmarking-country-substitution-policies.html 2022-04-04T13:31:08+00:00 https://gabi-journal-net.server1.ech.be/20174-gabi-journal-table-of-contents.html 2022-04-04T13:32:49+00:00 https://gabi-journal-net.server1.ech.be/hiv-patients-will-accept-generic-treatments.html 2022-04-04T13:33:39+00:00 https://gabi-journal-net.server1.ech.be/building-stakeholder-confidence-in-biosimilar-medicines-through-evidence-based-information-sharing.html 2022-04-04T13:36:35+00:00 https://gabi-journal-net.server1.ech.be/perspectives-on-the-future-of-pegfilgrastim-biosimilars.html 2022-04-04T13:37:43+00:00 https://gabi-journal-net.server1.ech.be/randomized-non-inferiority-trial-fails-to-find-inferiority-switching-from-infliximab-originator-to-ct-p13-biosimilar.html 2022-04-04T13:38:10+00:00 https://gabi-journal-net.server1.ech.be/a-comparison-of-european-and-us-generic-drug-markets.html 2022-04-04T13:38:33+00:00 https://gabi-journal-net.server1.ech.be/20171-gabi-journal-table-of-contents.html 2022-04-04T14:19:40+00:00 https://gabi-journal-net.server1.ech.be/20141-gabi-journal-table-of-contents.html 2022-04-04T14:21:07+00:00 https://gabi-journal-net.server1.ech.be/value-added-medicines-how-repurposed-medicines-bring-value-to-patients-and-pharmacists.html 2022-04-05T06:55:53+00:00 https://gabi-journal-net.server1.ech.be/first-gcc-stakeholder-meeting-on-approval-process-interchangeability-substitution-and-safety-of-biosimilars-2017-report.html 2022-04-06T07:02:05+00:00 https://gabi-journal-net.server1.ech.be/systematic-analysis-of-injection-site-pain-and-reactions-caused-by-subcutaneous-administration-of-the-adalimumab-biosimilar-fkb327-versus-the-adalimumab-reference-product-via-different-delivery-method.html 2022-04-06T12:24:35+00:00 https://gabi-journal-net.server1.ech.be/naming-and-labelling-of-biologicals-a-survey-of-us-physicians-perspectives.html 2022-04-07T08:11:03+00:00 https://gabi-journal-net.server1.ech.be/an-overview-of-the-current-status-of-follow-on-biologicals-in-iran.html 2022-04-07T14:17:42+00:00 https://gabi-journal-net.server1.ech.be/physician-associations-comment-on-fdas-interchangeability-guidance.html 2022-04-12T08:20:57+00:00 https://gabi-journal-net.server1.ech.be/major-lessons-learned-from-zarxios-us-launch-the-start-of-a-biosimilar-revolution.html 2022-04-12T08:35:17+00:00 https://gabi-journal-net.server1.ech.be/40th-anniversary-of-essential-medicines-a-loud-call-for-improving-its-access.html 2022-04-12T08:38:03+00:00 https://gabi-journal-net.server1.ech.be/biosimilars-in-germany-guidance-of-the-drug-commission-of-the-german-medical-association.html 2022-04-12T08:39:01+00:00 https://gabi-journal-net.server1.ech.be/usa-and-europe-differ-in-interchangeability-of-biosimilars.html 2022-04-12T08:40:14+00:00 https://gabi-journal-net.server1.ech.be/2021-4-gabi-journal-table-of-contents.html 2022-04-26T08:16:33+00:00 https://gabi-journal-net.server1.ech.be/2022-1-gabi-journal-table-of-contents.html 2022-07-27T05:40:49+00:00 https://gabi-journal-net.server1.ech.be/assessing-biosimilarity-and-interchangeability-of-biosimilar-products-under-the-biologics-price-competition-and-innovation-act.html 2022-08-01T08:19:41+00:00 https://gabi-journal-net.server1.ech.be/establishment-of-reference-standards-in-biosimilar-studies.html 2022-08-01T08:24:35+00:00 https://gabi-journal-net.server1.ech.be/european-prescribers-attitudes-and-beliefs-on-biologicals-prescribing-and-automatic-substitution.html 2022-08-22T09:00:58+00:00 https://gabi-journal-net.server1.ech.be/pharmaceutical-data-integrity-issues-challenges-and-proposed-solutions-for-manufacturers-and-inspectors.html 2022-08-22T09:17:04+00:00 https://gabi-journal-net.server1.ech.be/can-local-policies-on-biosimilars-optimize-the-use-of-freed-resources-experiences-from-italy.html 2022-08-22T09:18:30+00:00 https://gabi-journal-net.server1.ech.be/no-need-for-systematic-switch-studies-to-demonstrate-interchangeability-of-biosimilars.html 2022-09-07T18:05:06+00:00 https://gabi-journal-net.server1.ech.be/thank-you-to-reviewers-2021.html 2022-11-29T09:36:13+00:00 https://gabi-journal-net.server1.ech.be/2022-2-gabi-journal-table-of-contents.html 2022-11-29T10:09:30+00:00 https://gabi-journal-net.server1.ech.be/regulatory-pathway-for-approval-of-biosimilars-in-iran.html 2023-03-02T10:58:30+00:00 https://gabi-journal-net.server1.ech.be/why-similar-can-make-a-big-difference.html 2024-05-03T15:00:58+00:00 https://gabi-journal-net.server1.ech.be/barriers-to-market-uptake-of-biosimilars-in-the-us.html 2024-05-10T08:47:50+00:00 https://gabi-journal-net.server1.ech.be/infliximab-discontinuation-in-patients-with-originator-retransition-vs-biosimilar-continuation.html 2024-05-10T08:53:14+00:00 https://gabi-journal-net.server1.ech.be/biotechnological-therapies-and-biosimilars-for-covid-19-scarcities-poor-regulation-and-pharmaceutical-black-market-a-case-analysis-in-ecuador.html 2024-05-10T10:04:37+00:00 https://gabi-journal-net.server1.ech.be/biosimilarity-is-not-a-transitive-property-implication-for-interchangeability-naming-and-pharmacovigilance.html 2024-05-10T10:25:29+00:00 https://gabi-journal-net.server1.ech.be/challenges-in-the-manufacture-storage-distribution-and-regulation-of-traditional-and-novel-vaccines.html 2024-05-10T10:28:27+00:00 https://gabi-journal-net.server1.ech.be/biotherapeutic-products-in-the-european-pharmacopoeia-have-all-challenges-been-tackled.html 2024-05-10T10:31:52+00:00 https://gabi-journal-net.server1.ech.be/extended-stability-of-the-trastuzumab-biosimilar-abp-980-kanjinti-in-polyolefin-bags-and-elastomeric-devices.html 2024-05-10T10:35:11+00:00 https://gabi-journal-net.server1.ech.be/the-european-framework-for-intellectual-property-rights-for-biological-medicines.html 2024-05-10T10:35:56+00:00 https://gabi-journal-net.server1.ech.be/an-iprp-survey-of-the-regulatory-requirements-for-the-waiver-of-in-vivo-bioequivalence-studies-of-generic-medicinal-products-in-certain-dosage-forms.html 2024-05-10T10:37:08+00:00 https://gabi-journal-net.server1.ech.be/reasons-for-patients-generic-drug-switching-at-the-pharmacy-counter-a-pilot-study.html 2024-05-10T10:38:35+00:00 https://gabi-journal-net.server1.ech.be/pharmacokinetics-and-bioequivalence-of-generic-etoricoxib-in-healthy-volunteers.html 2024-05-10T10:39:33+00:00 https://gabi-journal-net.server1.ech.be/biosimilar-epoetin-for-cancer-and-chemotherapy-induced-anaemia-in-the-us.html 2024-05-10T10:40:30+00:00 https://gabi-journal-net.server1.ech.be/use-of-biologicals-in-dermatology-following-the-agreed-path-or-going-off-piste-a-brief-report.html 2024-05-10T10:41:14+00:00 https://gabi-journal-net.server1.ech.be/a-critical-review-of-substitution-policy-for-biosimilars-in-canada.html 2024-05-10T10:43:05+00:00 https://gabi-journal-net.server1.ech.be/microbiological-scientific-and-regulatory-perspectives-of-hand-sanitizers.html 2024-05-10T10:44:06+00:00 https://gabi-journal-net.server1.ech.be/biosimilars-status-in-july-2020-in-16-countries.html 2024-05-10T10:48:17+00:00 https://gabi-journal-net.server1.ech.be/patent-expiry-dates-for-biologicals-2018-update.html 2024-05-10T14:19:10+00:00 https://gabi-journal-net.server1.ech.be/stability-of-the-trastuzumab-biosimilar-abp-980-compared-to-reference-product-after-intravenous-bag-preparation-transport-and-storage-at-various-temperatures-concentrations-and-stress-conditions.html 2024-07-04T11:00:37+00:00 https://gabi-journal-net.server1.ech.be/extended-stability-of-a-biosimilar-of-trastuzumab-ct-p6-after-reconstitution-in-vials-dilution-in-polyolefin-bags-and-storage-at-various-temperatures.html 2024-07-04T11:01:37+00:00 https://gabi-journal-net.server1.ech.be/substitution-and-interchangeability-time-for-a-conversation.html 2024-07-19T10:28:46+00:00 https://gabi-journal-net.server1.ech.be/on-statistical-evaluation-for-interchangeability-of-biosimilar-products.html 2024-07-19T10:31:06+00:00 https://gabi-journal-net.server1.ech.be/a-case-study-of-astrazenecas-omeprazole-esomeprazole-chiral-switch-strategy.html 2024-07-19T10:35:31+00:00 https://gabi-journal-net.server1.ech.be/manufacture-and-regulation-of-cell-tissue-and-gene-therapy-products-global-perspectives-challenges-and-next-steps.html 2024-07-19T10:38:15+00:00 https://gabi-journal-net.server1.ech.be/development-of-ph-eur-standards-for-therapeutic-monoclonal-antibodies-infliximab-case-study.html 2024-07-19T11:50:03+00:00 https://gabi-journal-net.server1.ech.be/response-to-the-opinion-entitled-biosimilars-drug-development-time-for-a-paradigm-shift.html 2024-07-19T12:35:00+00:00 https://gabi-journal-net.server1.ech.be/pharmacokinetics-and-relative-bioavailability-of-sitagliptin-hydrochloride-and-sitagliptin-phosphate-tablets-formulations-a-randomized-open-label-crossover-study-in-healthy-male-volunteers.html 2024-07-19T12:43:39+00:00 https://gabi-journal-net.server1.ech.be/biosimilars-drug-development-time-for-a-paradigm-shift.html 2024-07-19T12:45:44+00:00 https://gabi-journal-net.server1.ech.be/trends-in-saudi-fda-drug-approvals-and-gmp-inspections-an-observational-study.html 2024-07-19T13:26:11+00:00 https://gabi-journal-net.server1.ech.be/switches-between-biosimilars-and-their-reference-products.html 2024-07-19T13:34:10+00:00 https://gabi-journal-net.server1.ech.be/promoting-access-to-biosimilars-a-public-private-partnership-model-for-biosimilar-development-in-underserved-populations.html 2024-07-22T09:20:36+00:00 https://gabi-journal-net.server1.ech.be/pharmacokinetic-bioequivalence-of-sitagliptin-phosphate-tablet-formulations-a-randomized-open-label-crossover-study-in-healthy-volunteers.html 2024-07-26T07:31:15+00:00 https://gabi-journal-net.server1.ech.be/long-acting-insulin-analogues-drug-selection-by-means-of-the-system-of-objectified-judgement-analysis-soja.html 2024-07-29T07:17:13+00:00 https://gabi-journal-net.server1.ech.be/canadian-prescribers-attitudes-and-perceptions-about-ophthalmic-biosimilars.html 2024-07-29T07:19:39+00:00 https://gabi-journal-net.server1.ech.be/statistical-tests-for-detecting-reference-product-change-in-biosimilar-studies.html 2024-07-29T07:21:14+00:00 https://gabi-journal-net.server1.ech.be/ethnic-sensitivity-assessments-in-biosimilar-monoclonal-antibodies-clinical-development-programmes-necessary-or-not.html 2024-07-29T07:22:01+00:00 https://gabi-journal-net.server1.ech.be/regulation-of-copy-biologicals-in-china.html 2024-07-31T07:37:35+00:00 https://gabi-journal-net.server1.ech.be/current-understanding-knowledge-and-perception-of-biosimilars-in-a-changing-landscape-of-regulatory-requirements.html 2024-08-08T17:18:18+00:00 https://gabi-journal-net.server1.ech.be/us-prescribers-attitudes-and-perceptions-about-biosimilars.html 2024-08-23T08:36:30+00:00 https://gabi-journal-net.server1.ech.be/biosimilars-in-italy-what-do-real-world-data-reveal.html 2024-09-05T15:43:00+00:00 https://gabi-journal-net.server1.ech.be/extended-stability-data-on-small-molecule-anticancer-medicinal-products-anything-new-any-additional-information-necessary.html 2024-09-30T14:37:46+00:00 https://gabi-journal-net.server1.ech.be/comparative-efficacy-studies-of-biosimilars-data-versus-theoretical-risks-beliefs-and-comfort.html 2024-10-31T11:21:43+00:00 https://gabi-journal-net.server1.ech.be/preserve-the-us-interchangeable-standard-that-has-helped-drive-physician-and-patient-confidence-in-biosimilars.html 2024-10-31T11:23:13+00:00 https://gabi-journal-net.server1.ech.be/physicochemical-stability-of-cabazitaxel-accord-in-punctured-original-vials-and-after-dilution-with-0-9-sodium-chloride-or-5-glucose-solution-in-non-pvc-bottles.html 2024-11-15T14:54:14+00:00 https://gabi-journal-net.server1.ech.be/physicochemical-stability-of-carboplatin-accord-in-punctured-original-vials-syringes-and-after-dilution-with-0-9-sodium-chloride-or-5-glucose-solution.html 2024-11-15T14:54:44+00:00 https://gabi-journal-net.server1.ech.be/physicochemical-stability-of-cytarabine-accord-in-punctured-original-vials-and-after-dilution-with-0-9-sodium-chloride-solution-in-polyolefine-bags.html 2024-11-15T14:55:48+00:00 https://gabi-journal-net.server1.ech.be/physicochemical-stability-of-docetaxel-accord-20-mg-ml-concentrate-diluted-with-0-9-sodium-chloride-or-5-glucose-solution-in-non-pvc-bags.html 2024-11-15T14:56:12+00:00 https://gabi-journal-net.server1.ech.be/physicochemical-stability-of-doxorubicin-accord-2-mg-ml-in-punctured-original-vials-and-polypropylene-syringes-and-after-dilution-with-0-9-sodium-chloride-or-5-glucose-solution-in-polyethylene-bottles.html 2024-11-15T14:56:33+00:00 https://gabi-journal-net.server1.ech.be/physicochemical-stability-of-epirubicin-accord-2-mg-ml-in-punctured-original-vials-and-polypropylene-syringes-and-after-dilution-with-0-9-sodium-chloride-or-5-glucose-solution-in-polyolefine-bags.html 2024-11-15T14:56:51+00:00 https://gabi-journal-net.server1.ech.be/physicochemical-stability-of-fluorouracil-accord-in-three-different-concentrations-in-portable-elastomeric-infusion-pumps.html 2024-11-15T14:58:08+00:00 https://gabi-journal-net.server1.ech.be/physicochemical-stability-of-gemcitabine-accord-100-mg-ml-in-punctured-original-vials-and-after-dilution-with-0-9-sodium-chloride-in-polyolefine-bags.html 2024-11-15T14:58:34+00:00 https://gabi-journal-net.server1.ech.be/physicochemical-stability-of-idarubicin-accord-in-punctured-original-vials-syringes-and-after-dilution-with-water-for-injection.html 2024-11-15T14:58:53+00:00 https://gabi-journal-net.server1.ech.be/physicochemical-stability-of-irinotecan-accord-in-punctured-original-vials-and-polypropylene-syringes-and-after-dilution-with-0-9-sodium-chloride-or-5-glucose-solution-in-polyolefine-bags.html 2024-11-15T14:59:20+00:00 https://gabi-journal-net.server1.ech.be/physicochemical-stability-of-methotrexate-accord-in-punctured-original-vials-and-after-dilution-with-0-9-sodium-chloride-or-5-glucose-solution-in-non-pvc-bags.html 2024-11-15T14:59:43+00:00 https://gabi-journal-net.server1.ech.be/physicochemical-stability-of-mitoxantrone-accord-after-dilution-with-0-9-sodium-chloride-solution-in-polyolefine-bags.html 2024-11-15T15:00:07+00:00 https://gabi-journal-net.server1.ech.be/physicochemical-stability-of-oxaliplatin-accord-5-mg-ml-in-punctured-original-vials-and-after-dilution-with-5-glucose-solution-in-polyethylene-bottles-and-polyolefine-bags.html 2024-11-15T15:00:28+00:00 https://gabi-journal-net.server1.ech.be/physicochemical-stability-of-pemetrexed-accord-25-mg-ml-in-punctured-original-vials-and-after-dilution-with-0-9-sodium-chloride-solution-in-non-pvc-bottles.html 2024-11-15T15:01:06+00:00 https://gabi-journal-net.server1.ech.be/physicochemical-stability-of-topotecan-accord-after-dilution-with-0-9-sodium-chloride-or-5-glucose-solution-in-polyolefine-and-non-pvc-bags.html 2024-11-15T15:01:39+00:00 https://gabi-journal-net.server1.ech.be/physicochemical-stability-of-vinorelbine-accord-in-punctured-original-vials-and-after-dilution-with-0-9-sodium-chloride-or-5-glucose-solution.html 2024-11-15T15:02:06+00:00 https://gabi-journal-net.server1.ech.be/misinformation-about-interchangeable-biosimilars-undermines-us-health-policy-physician-confidence-and-patient-health.html 2025-01-17T13:30:13+00:00 https://gabi-journal-net.server1.ech.be/physicochemical-stability-of-etoposide-accord-in-punctured-original-vials-and-after-dilution-with-0-9-sodium-chloride-or-5-glucose-solution.html 2025-01-23T09:37:34+00:00 https://gabi-journal-net.server1.ech.be/physicochemical-stability-of-cisplatin-accord-in-punctured-original-vials-syringes-and-after-dilution-with-0-9-sodium-chloride-solution.html 2025-02-03T08:02:29+00:00 https://gabi-journal-net.server1.ech.be/the-potential-of-generics-policies-more-room-for-exploitation-ppri-conference-report.html 2025-02-26T17:35:33+00:00 https://gabi-journal-net.server1.ech.be/1047.html 2025-03-25T08:26:59+00:00 https://gabi-journal-net.server1.ech.be/non-medical-switching-of-biologicals-biosimilars-canada-europe-and-the-us-a-webinar-report.html 2025-03-30T11:27:19+00:00 https://gabi-journal-net.server1.ech.be/physicochemical-stability-of-azacitidine-accord-25-mg-ml-suspension-for-injection-in-original-vials-and-polypropylene-syringes-after-reconstitution-with-refrigerated-water-for-injection.html 2025-04-02T07:47:19+00:00 https://gabi-journal-net.server1.ech.be/follow-on-biologicals-biosimilars-approved-in-brazil-may-2023-update.html 2025-04-16T08:56:02+00:00 https://gabi-journal-net.server1.ech.be/do-low-to-middle-income-countries-need-a-biosimilar-approval-pathway-based-on-a-full-comparability-exercise.html 2025-04-16T15:26:14+00:00 https://gabi-journal-net.server1.ech.be/low-cost-generic-drug-programs-in-the-us-implications-for-payers-and-researchers.html 2025-04-16T15:29:37+00:00 https://gabi-journal-net.server1.ech.be/do-pricing-and-usage-enhancing-policies-differ-between-biosimilars-and-generics-findings-from-an-international-survey.html 2025-04-16T15:31:32+00:00 https://gabi-journal-net.server1.ech.be/differences-in-pharmacokinetic-behaviour-of-branded-enoxaparin-and-a-us-generic-version-in-a-non-human-primate-model.html 2025-04-16T15:32:41+00:00 https://gabi-journal-net.server1.ech.be/equivalence-of-generic-medicines-in-general-and-immunosuppressants-in-particular-a-regulatory-opinion-on-switching-of-ciclosporin-tacrolimus-and-mycophenolate-mofetil.html 2025-04-16T15:33:37+00:00 https://gabi-journal-net.server1.ech.be/variation-in-the-prices-of-oncology-medicines-across-europe-and-the-implications-for-the-future.html 2025-04-16T15:37:51+00:00 https://gabi-journal-net.server1.ech.be/role-of-hospital-clinical-pharmacist-in-transplantation-and-generic-immunosuppressive-therapies.html 2025-04-16T15:41:29+00:00 https://gabi-journal-net.server1.ech.be/recent-trends-and-special-topics-in-new-drug-review-in-pmda.html 2025-04-16T15:48:01+00:00 https://gabi-journal-net.server1.ech.be/defining-and-characterizing-non-biological-complex-drugs-nbcds-is-size-enough-the-case-for-liposomal-doxorubicin-generics-liposomal-nanosimilars-for-injection.html 2025-04-16T15:49:55+00:00 https://gabi-journal-net.server1.ech.be/2nd-mena-stakeholder-meeting-on-biosimilars-2018-report.html 2025-04-16T15:52:39+00:00 https://gabi-journal-net.server1.ech.be/implementing-a-treatment-registry-for-a-biosimilar-continuous-safety-surveillance-of-the-biosimilar-bevax-bevacizumab-in-argentina.html 2025-04-16T15:54:47+00:00 https://gabi-journal-net.server1.ech.be/biosimilar-monoclonal-antibodies-approved-for-use-in-the-eu.html 2025-04-16T15:55:56+00:00 https://gabi-journal-net.server1.ech.be/generics-substitution-in-primary-care-summary-of-the-dutch-community-pharmacies-guidelines.html 2025-04-16T16:00:40+00:00 https://gabi-journal-net.server1.ech.be/adjusted-indirect-comparisons-between-generics-bioequivalence-and-interchangeability.html 2025-04-16T16:03:01+00:00 https://gabi-journal-net.server1.ech.be/clinical-development-immunogenicity-and-interchangeability-of-follow-on-complex-drugs.html 2025-04-16T16:06:12+00:00 https://gabi-journal-net.server1.ech.be/first-asia-pacific-educational-workshop-on-non-biological-complex-drugs-nbcds-kuala-lumpur-malaysia-8-october-2013.html 2025-04-16T16:07:37+00:00 https://gabi-journal-net.server1.ech.be/a-progress-report-on-the-3rd-international-symposium-on-scientific-and-regulatory-advances-in-biological-and-non-biological-complex-drugs-a-to-z-in-bioequivalence.html 2025-04-16T16:13:10+00:00 https://gabi-journal-net.server1.ech.be/non-biological-complex-drugs-nbcds-and-their-follow-on-versions-time-for-an-editorial-section.html 2025-04-16T16:15:27+00:00 https://gabi-journal-net.server1.ech.be/overview-of-non-innovator-biological-products-in-india.html 2025-04-16T16:19:01+00:00 https://gabi-journal-net.server1.ech.be/medicines-regulation-in-the-mena-region-and-the-importance-of-the-world-health-organizations-inn-proposal-of-biological-qualifier.html 2025-04-16T16:21:23+00:00 https://gabi-journal-net.server1.ech.be/first-mena-educational-workshop-on-regulation-and-approval-of-similar-biotherapeutic-products-biosimilars-dubai-united-arab-emirates-1-september-2015.html 2025-04-16T16:23:41+00:00 https://gabi-journal-net.server1.ech.be/the-authorization-of-non-biological-complex-drugs-nbcds-follow-on-versions-specific-regulatory-and-interchangeability-rules-ahead.html 2025-04-16T16:28:50+00:00 https://gabi-journal-net.server1.ech.be/comment-on-the-non-biological-complex-drugs-paper.html 2025-04-16T16:29:59+00:00 https://gabi-journal-net.server1.ech.be/the-implementation-of-generics-in-france.html 2025-04-16T16:34:55+00:00 https://gabi-journal-net.server1.ech.be/tyrosine-kinase-inhibitors-becoming-generic-drugs-risks-and-chances-from-a-regulatory-perspective.html 2025-04-16T16:41:38+00:00 https://gabi-journal-net.server1.ech.be/pharmacokinetics-of-antimicrobials-in-obese-children.html 2025-04-16T16:46:04+00:00 https://gabi-journal-net.server1.ech.be/ever-changing-landscape-of-biosimilars-in-canada-findings-and-implications-from-a-global-perspective.html 2025-04-16T16:50:26+00:00 https://gabi-journal-net.server1.ech.be/understanding-the-components-of-pharmaceutical-expenditure-overview-of-pharmaceutical-policies-influencing-expenditure-across-european-countries.html 2025-04-16T16:51:14+00:00 https://gabi-journal-net.server1.ech.be/biosimilars-naming-label-transparency-and-authority-of-choice-survey-findings-among-european-physicians.html 2025-04-16T16:52:20+00:00 https://gabi-journal-net.server1.ech.be/ongoing-initiatives-to-improve-prescribing-efficiency-in-china-statins-as-a-case-history.html 2025-04-16T16:54:46+00:00 https://gabi-journal-net.server1.ech.be/social-trust-and-regional-variation-in-the-adoption-of-biosimilars-in-italy-and-germany.html 2025-04-16T16:55:53+00:00 https://gabi-journal-net.server1.ech.be/biosimilars-achieving-long-term-savings-and-competitive-markets.html 2025-04-16T16:57:09+00:00 https://gabi-journal-net.server1.ech.be/pharmaceutical-pricing-in-croatia-a-comparison-of-ordinances-in-2013-versus-2009-and-their-potential-savings-to-provide-future-guidance.html 2025-04-16T16:58:24+00:00 https://gabi-journal-net.server1.ech.be/product-naming-pricing-and-market-uptake-of-biosimilars.html 2025-04-16T17:00:52+00:00 https://gabi-journal-net.server1.ech.be/complex-molecules-current-developments.html 2025-04-16T17:01:52+00:00 https://gabi-journal-net.server1.ech.be/quality-assessment-of-biosimilars-in-colombia-reducing-knowledge-gaps.html 2025-04-16T17:02:32+00:00 https://gabi-journal-net.server1.ech.be/the-refinement-of-the-super-generic-concept-semantic-challenge-for-product-re-innovation.html 2025-04-16T17:07:46+00:00 https://gabi-journal-net.server1.ech.be/availability-and-procurement-conditions-of-originator-and-generic-medicines-in-hospitals-an-exploratory-study-in-five-medium-sized-european-countries.html 2025-04-16T17:10:45+00:00 https://gabi-journal-net.server1.ech.be/patent-expiry-and-costs-for-anticancer-medicines-for-clinical-use.html 2025-04-16T17:11:52+00:00 https://gabi-journal-net.server1.ech.be/3rd-colombian-educational-workshop-on-regulatory-assessment-of-biosimilars-2019-report.html 2025-04-16T17:16:05+00:00 https://gabi-journal-net.server1.ech.be/increasing-adoption-of-quality-assured-biosimilars-to-address-access-challenges-in-low-and-middle-income-countries.html 2025-04-17T13:01:57+00:00 https://gabi-journal-net.server1.ech.be/medicare-drug-price-negotiations-impact-on-healthcare-development-and-patient-access-to-medicines.html 2025-06-27T13:38:09+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Michael-Reilly-V22F17RP.jpg https://gabi-journal-net.server1.ech.be/roundtable-on-registries-practical-considerations-for-registries-making-them-work-london-uk-26-january-2017.html 2025-06-27T13:51:20+00:00 https://gabi-journal-net.server1.ech.be/aligning-environmental-social-and-governance-to-clinical-development-moving-towards-more-sustainable-clinical-trials.html 2025-07-09T08:54:57+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/image-edited.jpeg https://gabi-journal-net.server1.ech.be/us-interchangeability-designation-are-we-ready-to-cut-the-gordian-knot.html 2025-07-09T09:10:56+00:00 https://gabi-journal-net.server1.ech.be/the-challenge-for-drug-shortage-lessons-learned-from-the-quality-issues-of-japanese-generic-drug-companies.html 2025-07-09T09:46:19+00:00 https://gabi-journal-net.server1.ech.be/summative-usability-evaluation-of-the-ylb113-etanercept-biosimilar-autoinjector-via-simulation.html 2025-08-13T13:34:28+00:00 https://gabi-journal-net.server1.ech.be/2024-3-gabi-journal-table-of-contents.html 2025-10-16T13:06:22+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2024-1-Cover-Web-V24H08.png https://gabi-journal-net.server1.ech.be/2022-3-gabi-journal-table-of-contents.html 2025-10-16T14:30:19+00:00 https://gabi-journal-net.server1.ech.be/top-developments-in-biosimilars-during-2019.html 2025-10-16T17:05:48+00:00 https://gabi-journal-net.server1.ech.be/top-developments-in-biosimilars-during-2018.html 2025-10-16T17:06:03+00:00 https://gabi-journal-net.server1.ech.be/a-review-of-international-initiatives-on-pharmaceutical-regulatory-reliance-and-recognition.html 2025-10-28T14:26:08+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ2024-2p154Fig1-1.jpg https://gabi-journal-net.server1.ech.be/transforming-healthcare-cinnagens-leadership-in-follow-on-biologicals-biosimilars-development-and-market-expansion.html 2025-10-28T14:27:52+00:00 https://gabi-journal-net.server1.ech.be/biosimilar-antibody-drug-conjugates-considerations-of-higher-order-structure-and-aggregation.html 2025-10-29T17:39:20+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2023-3-p108Fig1.jpg https://gabi-journal-net.server1.ech.be/front-loading-biosimilar-development-with-analytical-characterization.html 2025-10-29T17:41:03+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2022-2-p83-Tab1.jpg https://gabi-journal-net.server1.ech.be/structural-characterization-methods-for-biosimilars-fit-for-purpose-qualified-or-validated.html 2025-10-29T17:42:59+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2022-1-p42Tab1.jpg https://gabi-journal-net.server1.ech.be/the-incorporation-of-the-halal-management-system-hms-by-the-pharmaceutical-industry.html 2025-12-16T15:51:44+00:00 https://gabi-journal-net.server1.ech.be/editors-introduction-to-the-initial-issue-of-the-14th-volume-of-gabi-journal.html 2026-01-15T17:42:20+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2025-1-cover-V25J16CM.jpg https://gabi-journal-net.server1.ech.be/third-and-final-issue-of-gabi-journals-13th-volume.html 2026-01-15T17:45:56+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2024-3-cover-V25B09VK.jpg https://gabi-journal-net.server1.ech.be/what-to-look-forward-to-in-gabi-journal-2024-issue-2.html 2026-01-15T17:46:32+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2024-2-cover-V24J09VK.jpg https://gabi-journal-net.server1.ech.be/first-2024-gabi-journal-issue-highlights.html 2026-01-15T17:50:34+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2024-1-COVER-V24G25VK.jpg https://gabi-journal-net.server1.ech.be/latest-features-in-gabi-journal-2023-issue-3.html 2026-01-15T17:51:43+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2023-3-Cover-Web-V24H08AA.png https://gabi-journal-net.server1.ech.be/extrapolation-requires-reading-between-the-lines.html 2026-01-15T17:52:32+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2023-2-Cover-Web-V24H08AA-1.png https://gabi-journal-net.server1.ech.be/lagging-acceptance-of-generic-and-biosimilar-drug-products-the-rest-of-the-story.html 2026-01-15T17:53:27+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2023-1-Cover-Web-V24H08AA.png https://gabi-journal-net.server1.ech.be/the-importance-of-trust.html 2026-01-15T17:54:20+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2022-3-Cover-Web-V24H08AA.png https://gabi-journal-net.server1.ech.be/what-to-look-forward-to-in-gabi-journal-2022-issue-2.html 2026-01-15T17:55:15+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2022-2-Cover-Web-V24H08AA.png https://gabi-journal-net.server1.ech.be/first-2022-gabi-journal-issue-highlights.html 2026-01-15T17:56:23+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2022-1-Cover-Web-V22I28MY.png https://gabi-journal-net.server1.ech.be/fourth-and-final-issue-of-gabi-journals-10th-volume.html 2026-01-15T17:57:27+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2021-4-Cover-Web-V22E23AU.jpg https://gabi-journal-net.server1.ech.be/latest-features-in-gabi-journal-2021-issue-3.html 2026-01-15T17:58:30+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2021-3-Cover-Web-V22E23AU-1.jpg https://gabi-journal-net.server1.ech.be/what-to-look-forward-to-in-gabi-journal-2021-issue-2.html 2026-01-15T18:11:10+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2021-2-Cover-Web-V21I29MN.jpg https://gabi-journal-net.server1.ech.be/first-2021-gabi-journal-issue-highlights.html 2026-01-15T18:12:15+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2021-1-Cover-Web-V21D29MN.jpg https://gabi-journal-net.server1.ech.be/medical-journal-publication-during-global-stress.html 2026-01-15T18:13:37+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2020-4-Cover-Web-V21D29MN.jpg https://gabi-journal-net.server1.ech.be/latest-features-in-gabi-journal-2020-issue-3.html 2026-01-15T18:14:20+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2020-3-Cover-Web-V21I30MN.jpg https://gabi-journal-net.server1.ech.be/what-to-look-forward-to-in-gabi-journal-2020-issue-2.html 2026-01-15T18:15:35+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2020-2-Cover-Web-V20I30LS.jpg https://gabi-journal-net.server1.ech.be/editors-introduction-to-the-initial-issue-of-the-ninth-volume-of-gabi-journal.html 2026-01-15T18:16:46+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2020-1-Cover-Web-V20G06LS.jpg https://gabi-journal-net.server1.ech.be/latest-features-in-gabi-journal-2019-issue-3.html 2026-01-15T18:17:52+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2019-3-Cover-Web-V20C30LSAZ.jpg https://gabi-journal-net.server1.ech.be/unmet-potential-of-generics-and-biosimilars-to-reduce-healthcare-costs.html 2026-01-15T18:18:37+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2019-2-Cover-Web-V19L05LS.jpg https://gabi-journal-net.server1.ech.be/editors-introduction-to-the-initial-issue-of-the-eighth-volume-of-gabi-journal.html 2026-01-15T18:20:01+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2019-1-Cover-Web-V19F03LS.jpg https://gabi-journal-net.server1.ech.be/fourth-and-final-issue-of-gabi-journals-seventh-volume.html 2026-01-15T18:21:26+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2018-4-Cover-Web-V19B27LS.jpg https://gabi-journal-net.server1.ech.be/latest-features-in-gabi-journal-2018-issue-3.html 2026-01-15T18:22:25+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2018-3-Cover-Web-V19A25LB.jpg https://gabi-journal-net.server1.ech.be/what-to-look-forward-to-in-gabi-journal-2018-issue-2.html 2026-01-15T18:23:13+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2018-2-Cover-Web-V18K28LB-1.jpg https://gabi-journal-net.server1.ech.be/editors-introduction-to-the-initial-issue-of-the-seventh-volume-of-gabi-journal.html 2026-01-15T18:24:18+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2018-1-Cover-Web-V18K28LB-3.jpg https://gabi-journal-net.server1.ech.be/fourth-and-final-issue-of-gabi-journals-sixth-volume.html 2026-01-15T18:25:17+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2017-4-Cover-Web-V18K28LB-3.jpg https://gabi-journal-net.server1.ech.be/latest-features-in-gabi-journal-2017-issue-3.html 2026-01-15T18:26:03+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2017-3-Cover-Web-V18K28LB-1.jpg https://gabi-journal-net.server1.ech.be/what-to-look-forward-to-in-gabi-journal-2017-issue-2.html 2026-01-15T18:26:47+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2017-2-Cover-Web-V18K28LB-1.jpg https://gabi-journal-net.server1.ech.be/editors-introduction-to-the-initial-issue-of-the-sixth-volume-of-gabi-journal.html 2026-01-15T18:27:31+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2017-1-Cover-Web-V18K28LB-1.jpg https://gabi-journal-net.server1.ech.be/fourth-and-final-issue-of-gabi-journals-fifth-volume.html 2026-01-15T18:28:31+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2016-4-Cover-Web-V18K28LB-1.jpg https://gabi-journal-net.server1.ech.be/latest-features-in-gabi-journal-2016-issue-3.html 2026-01-15T18:29:23+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2016-3-Cover-Web-V18K28LB-1.jpg https://gabi-journal-net.server1.ech.be/what-to-look-forward-to-in-gabi-journal-2016-issue-2.html 2026-01-15T18:30:05+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2016-2-Cover-Web-V18K28LB-1.jpg https://gabi-journal-net.server1.ech.be/editors-introduction-to-the-initial-issue-of-the-fifth-volume-of-gabi-journal.html 2026-01-15T18:31:17+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2016-1-Cover-Web-V18K28LB-1.jpg https://gabi-journal-net.server1.ech.be/fourth-and-final-issue-of-gabi-journals-fourth-volume.html 2026-01-15T18:32:26+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2015-4-Cover-Web-V18K28LB-1.jpg https://gabi-journal-net.server1.ech.be/latest-features-in-gabi-journal-2015-issue-3.html 2026-01-15T18:33:09+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2015-3-Cover-Web-V18K28LB-1.jpg https://gabi-journal-net.server1.ech.be/what-to-look-forward-to-in-gabi-journal-2015-issue-2.html 2026-01-15T18:34:38+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2015-2-Cover-Web-V18K28LB-1.jpg https://gabi-journal-net.server1.ech.be/editors-introduction-to-the-initial-issue-of-the-fourth-volume-of-gabi-journal.html 2026-01-15T18:35:41+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2015-1-Cover-Web-V18K28LB-1.jpg https://gabi-journal-net.server1.ech.be/fourth-and-final-issue-of-gabi-journals-third-volume.html 2026-01-15T18:36:55+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2014-4-Cover-Web-V18K28LB-1.jpg https://gabi-journal-net.server1.ech.be/latest-features-in-gabi-journal-2014-issue-3.html 2026-01-15T18:37:39+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2014-3-Cover-Web-V18K28LB-1.jpg https://gabi-journal-net.server1.ech.be/what-to-look-forward-to-in-gabi-journal-2014-issue-2.html 2026-01-15T18:38:34+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2014-2-Cover-web-V18K28LB-1.jpg https://gabi-journal-net.server1.ech.be/editors-introduction-to-the-initial-issue-of-the-third-volume-of-gabi-journal.html 2026-01-15T18:39:35+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2014-1-Cover-web-V18K28LB-1.jpg https://gabi-journal-net.server1.ech.be/gabi-journal-publishes-four-issues-in-2013.html 2026-01-15T18:40:41+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2013-4-cover-web-V18K28LB-1.jpg https://gabi-journal-net.server1.ech.be/latest-features-in-gabi-journal-2013-issue-3.html 2026-01-15T18:41:28+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2013-3-cover-web-V18K28LB-1.jpg https://gabi-journal-net.server1.ech.be/what-to-look-forward-to-in-gabi-journal-2013-issue-2.html 2026-01-15T18:42:18+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2013-2-cover-web-V18K28LB-1.jpg https://gabi-journal-net.server1.ech.be/editors-introduction-to-the-wide-range-of-topics-in-the-initial-issue-of-the-second-volume-of-gabi-journal.html 2026-01-15T18:43:21+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2013-1-cover-web-V18K28LB-1.jpg https://gabi-journal-net.server1.ech.be/latest-features-in-gabi-journal-2012-issue-3-4.html 2026-01-15T18:44:11+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2012-3-4-cover-web-V18K28LB-1.jpg https://gabi-journal-net.server1.ech.be/what-to-look-forward-to-in-gabi-journal-2012-issue-2.html 2026-01-15T18:44:59+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2012-2-cover-web-V18K28LB-2.jpg https://gabi-journal-net.server1.ech.be/introduction-to-the-gabi-journal.html 2026-01-15T18:49:54+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2012-1-cover-web-V18K28LB-2.jpg https://gabi-journal-net.server1.ech.be/budget-impact-analysis-of-a-rituximab-intravenous-biosimilar-in-patients-with-follicular-lymphoma-and-large-b-cell-non-hodgkin-lymphoma-in-chile.html 2026-01-20T15:15:52+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2024-1p5Fig1-2.jpg https://gabi-journal-net.server1.ech.be/pharmacokinetic-bioequivalence-studies-of-a-new-etoricoxib-tablet-formulation-developed-using-proprietary-mist-technology-risk-assessment-and-mitigation-using-gastroplus-software.html 2026-01-20T15:22:16+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ2024-1p2Fig1.jpg https://gabi-journal-net.server1.ech.be/key-factors-for-successful-uptake-of-biosimilars-europe-and-the-us.html 2026-01-21T14:08:34+00:00 https://gabi-journal-net.server1.ech.be/physicochemical-stability-of-fludarabine-accord-in-punctured-original-vials-and-after-dilution-with-0-9-sodium-chloride-solution.html 2026-01-23T17:49:40+00:00 https://gabi-journal-net.server1.ech.be/turkeys-biotech-manufacturing-ambitions-yerlika-biopharmas-strategic-role.html 2026-01-27T09:46:41+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ1-17-Yerlika-Hasan-Zeytin-V25D09MF.jpg https://gabi-journal-net.server1.ech.be/letter-to-the-editor-to-comment-the-article-reilly-ms-and-mckibbin-rd.html 2026-02-04T11:33:03+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/Efficacy-Extrapolation-Interchangeability-V13D19.jpg https://gabi-journal-net.server1.ech.be/biosimilar-red-tape-elimination-act-s-2305-weakening-fda-regulatory-standards-for-biosimilars-undermining-physician-confidence-and-jeopardizing-patient-health.html 2026-02-04T11:36:40+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/SO001402.jpg https://gabi-journal-net.server1.ech.be/comment-on-misinformation-about-interchangeable-biosimilars.html 2026-02-04T11:39:09+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/56-AA011042.jpg https://gabi-journal-net.server1.ech.be/a-spectrum-of-generics-and-biosimilars-research-reports-and-interviews.html 2026-02-04T13:12:24+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2025-2-cover-V26A21CM.jpg https://gabi-journal-net.server1.ech.be/therapeutic-equivalence-of-a-formulation-of-purified-micronized-flavonoid-fraction-of-diosmin-hesperidin-450-mg-50-mg-in-healthy-adults-an-open-label-randomized-single-dose-crossover-study.html 2026-02-04T13:13:56+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/130-AA008570.jpg https://gabi-journal-net.server1.ech.be/biosimilar-trial-failed-investors-get-their-money-back-a-new-insurance-model-redefines-clinical-trial-financing.html 2026-02-04T13:26:49+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/04-AA010978.jpg https://gabi-journal-net.server1.ech.be/follow-on-biologicals-biosimilars-approved-in-brazil-september-2025-update.html 2026-02-04T14:49:53+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/02-AA010638.jpg https://gabi-journal-net.server1.ech.be/an-analysis-of-policy-impacts-on-the-price-developments-of-biological-medicines-after-patent-expiration.html 2026-02-04T18:53:56+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/24-AA011041.jpg https://gabi-journal-net.server1.ech.be/current-trends-in-biosimilar-uptake-and-special-focus-on-automatic-substitution-a-symposium-report.html 2026-02-06T10:13:08+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ2-20-Bios-Symp-2025-66-V25F26.png https://gabi-journal-net.server1.ech.be/physicochemical-stability-of-bortezomib-accord-2-5-mg-ml-and-diluted-1-mg-ml-intravenous-injection-solution-in-punctured-original-vials-and-polypropylene-syringes.html 2026-02-06T10:17:36+00:00 https://gabi-journal-net.server1.ech.be/biosimilars-in-oncology-beyond-regulation-building-confidence-through-evidence-and-dialogue.html 2026-02-06T11:32:37+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2025-3-p81-Fig2.png https://gabi-journal-net.server1.ech.be/rising-costs-of-biologicals-effective-cost-containment-does-not-please-all-stakeholders.html 2026-02-06T13:18:35+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/15-AA010699.jpg https://gabi-journal-net.server1.ech.be/effective-and-safe-handling-of-pre-filled-syringe-pfs-for-administration-of-biosimilar-candidate-avt06-aflibercept-in-patients-with-chorioretinal-vascular-diseases.html 2026-02-06T13:27:27+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2025-3-p86-Fig1.png https://gabi-journal-net.server1.ech.be/australian-biosimilar-policies-not-delivering-on-intended-outcomes-where-to-from-here.html 2026-02-06T14:00:53+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2025-3-p94-Fig1.png https://gabi-journal-net.server1.ech.be/clear-naming-traceability-of-biological-medicines-will-protect-patients.html 2026-03-17T17:42:23+00:00 https://gabi-journal-net.server1.ech.be/biosimilars-still-safe-still-effective-still-not-generics-why-is-the-fda-suddenly-pretending-they-are.html 2026-05-13T15:44:56+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/50-MD002352.jpg https://gabi-journal-net.server1.ech.be/a-bioequivalence-study-of-paliperidone-palmitate-once-monthly-156-mg-ml-extended-release-injectable-in-patients-with-schizophrenia.html 2026-05-13T16:20:14+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/MS-Nerve-cells-V13C03.jpg https://gabi-journal-net.server1.ech.be/new-research-in-biosimilars-oncology-barriers-pfs-handling-and-australian-policy.html 2026-05-14T08:57:58+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2025-3-cover-V26E08CM.jpg https://gabi-journal-net.server1.ech.be/budget-impact-analysis-of-implementation-of-biosimilars-in-a-private-health-insurance-company-of-large-size-in-southern-brazil.html 2026-05-14T10:34:30+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/16-AA010705.jpg https://gabi-journal-net.server1.ech.be/real-world-evaluation-of-dosing-and-haemoglobin-a1c-hba1c-in-patients-converted-from-insulin-glargine-lantus-to-insulin-glargine-basaglar-in-saudi-arabia.html 2026-05-14T10:35:30+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/63-MD002127.jpg https://gabi-journal-net.server1.ech.be/barriers-to-expanding-biosimilars-in-oncological-indications-in-chile-a-value-chain-approach-to-understand-visions-and-propose-recommendations-for-improving-value-proposition.html 2026-05-22T10:53:00+00:00 https://gabi-journal-net.server1.ech.be/wp-content/uploads/GJ-2025-3-p76-Fig1.png